Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

University of Toronto

$37,000.00

Probing Ionizable Lipid Nanoparticles for Functional Delivery of Messenger RNA in Target Tissues

EF 2024-25

Résumé
In vivo delivery of messenger RNA (mRNA) has emerged with broad potential for treating and preventing a wide range of human pathologies, allowing protein replacement, vaccination, cancer immunotherapy, and genomic engineering. Safe and effective delivery strategies are essential to translating mRNA molecules from lab to bedside, among which ionizable lipid nanoparticles (LNPs) consist of four compositions (i.e., ionizable lipids, zwitterionic phospholipids, cholesterol, and PEGylated lipids) are clinically mature technology. Health Canada has approved two LNP-based mRNA vaccines for COVID-19. Although great advances have been made in mRNA vaccines, the ideal chemical and formulation composition of LNPs for extra-hepatic delivery of mRNA still needs to be discovered. This grant application aims to build high-throughput pipelines to synthesize, evaluate, and investigate new LNPs for tissue-selective mRNA delivery. Working at the interface between bioengineering, material chemistry, pharmaceutical sciences, molecular genetics, immunology, and synthetic biology, we will leverage high-throughput technology platforms (i.e., multicomponent reactions, DNA barcoding, and next-generation sequencing) to accelerate the discovery for precision mRNA delivery. The high-throughput combinatorial chemistry and multiplexed in vivo screening will allow us to rapidly create and characterize new LNPs at an unprecedented scale and speed. We will study the fundamental mechanisms of LNP targeting and define the essential physical and chemical properties of synthetic carriers required for tissue-selective delivery of mRNA, which can be used to inform the rational design of LNPs. In the short term, we will: 1. build a novel LNP toolbox for efficient systemic delivery of mRNA to extrahepatic tissues such as the lung, spleen, kidney, and intestine; 2. identify physiochemical properties of top-performing LNP formulations that are correlated to the mechanism of tissue-selective mRNA delivery; and 3. determine how the LNP compositions and the chemical structure of ionizable lipids affect cell-specific mRNA transfection in target tissues. This will open new avenues for designing and identifying novel LNP formulations for broader therapeutic applications of RNA. In the longer term, we aim to streamline the process of developing efficacious, safe, and clinically translatable LNPs for broad therapeutic applications of mRNA, which would provide colossal health and economic benefits to Canada.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RGPIN-2023-05124
Name nom
LI, BOWEN
Department département
Pharmaceutical Sciences
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2023
Award amount
37000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Probing Ionizable Lipid Nanoparticles for Functional Delivery of Messenger RNA in Target Tissues
Keywords
gene delivery; mrna delivery; drug delivery; biomaterials; lipid nanoparticles; nanomedicine; genome editing; bionanotechnology; nanomaterials; nucleic acids
Application summary
In vivo delivery of messenger RNA (mRNA) has emerged with broad potential for treating and preventing a wide range of human pathologies, allowing protein replacement, vaccination, cancer immunotherapy, and genomic engineering. Safe and effective delivery strategies are essential to translating mRNA molecules from lab to bedside, among which ionizable lipid nanoparticles (LNPs) consist of four compositions (i.e., ionizable lipids, zwitterionic phospholipids, cholesterol, and PEGylated lipids) are clinically mature technology. Health Canada has approved two LNP-based mRNA vaccines for COVID-19. Although great advances have been made in mRNA vaccines, the ideal chemical and formulation composition of LNPs for extra-hepatic delivery of mRNA still needs to be discovered. This grant application aims to build high-throughput pipelines to synthesize, evaluate, and investigate new LNPs for tissue-selective mRNA delivery. Working at the interface between bioengineering, material chemistry, pharmaceutical sciences, molecular genetics, immunology, and synthetic biology, we will leverage high-throughput technology platforms (i.e., multicomponent reactions, DNA barcoding, and next-generation sequencing) to accelerate the discovery for precision mRNA delivery. The high-throughput combinatorial chemistry and multiplexed in vivo screening will allow us to rapidly create and characterize new LNPs at an unprecedented scale and speed. We will study the fundamental mechanisms of LNP targeting and define the essential physical and chemical properties of synthetic carriers required for tissue-selective delivery of mRNA, which can be used to inform the rational design of LNPs. In the short term, we will: 1. build a novel LNP toolbox for efficient systemic delivery of mRNA to extrahepatic tissues such as the lung, spleen, kidney, and intestine; 2. identify physiochemical properties of top-performing LNP formulations that are correlated to the mechanism of tissue-selective mRNA delivery; and 3. determine how the LNP compositions and the chemical structure of ionizable lipids affect cell-specific mRNA transfection in target tissues. This will open new avenues for designing and identifying novel LNP formulations for broader therapeutic applications of RNA. In the longer term, we aim to streamline the process of developing efficacious, safe, and clinically translatable LNPs for broad therapeutic applications of mRNA, which would provide colossal health and economic benefits to Canada.